NCT04996823 - Axitinib + Ipilimumab in Advanced Melanoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 4, 2021

Primary Completion Date

August 20, 2026

Study Completion Date

March 29, 2027

Conditions

Melanoma

Interventions

DRUG

Ipilimumab

Participants will receive ipilimumab 3mg/kg IV every 3 weeks for up to 4 doses.

DRUG

Axitinib

Participants will take 5 mg Axitinib twice daily by mouth for up to 35 cycles (24 months)

Trial Locations (1)

RECRUITING

Moffitt Cancer Center, Tampa